PHE’s Stevens and Chou Address Variations in Cost-Effectiveness Studies of PCSK-9 Inhibitors in New Commentary for Journal of Medical Economics

PHE’s Warren Stevens and Jacquelyn Chou, along with coauthor Peter Toth, examine the markedly different cost-effectiveness study results for PCSK-9 inhibitors in a new commentary in the Journal of Medical Economics. The authors attribute the differences primarily to variations in assumptions about the risk of cardiovascular disease events. They examine what types of data are most appropriate for assessment of baseline MACE risk and are likely to yield the most accurate estimate of cost-effectiveness of PCSK-9 inhibitors for real-world patients. They argue that a systematic approach to modeling cost- effectiveness is needed.

To read the complete commentary, please click here.

Precision Medicine Group is an integrated team of experts in fields from advanced lab sciences to translational informatics and regulatory affairs, payer insights to marketing communications. Together, we help our pharmaceutical and life-sciences clients conquer product development and commercialization challenges in a rapidly evolving environment.